Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $38.00

Dianthus Therapeutics (NASDAQ:DNTH - Free Report) had its target price raised by Wedbush from $33.00 to $38.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages have also issued reports on DNTH. Raymond James boosted their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an outperform rating in a research report on Thursday, April 18th. Jefferies Financial Group upped their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a buy rating in a research report on Friday, March 22nd. Finally, Stifel Nicolaus began coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They set a buy rating and a $44.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of Buy and a consensus price target of $43.40.

Dianthus Therapeutics Stock Down 2.6 %

DNTH traded down $0.64 during trading on Friday, reaching $24.29. The company had a trading volume of 98,024 shares, compared to its average volume of 142,961. The business has a 50 day simple moving average of $25.50 and a 200-day simple moving average of $18.27. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. On average, sell-side analysts expect that Dianthus Therapeutics will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DNTH. FMR LLC purchased a new position in Dianthus Therapeutics during the third quarter valued at approximately $28,961,000. Acadian Asset Management LLC bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth $303,000. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth $3,240,000. Avidity Partners Management LP bought a new stake in Dianthus Therapeutics during the third quarter valued at about $16,644,000. Finally, Laurion Capital Management LP purchased a new position in Dianthus Therapeutics in the third quarter valued at about $497,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.